<DOC>
	<DOCNO>NCT02941991</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability hESC-RPE cellular therapy patient advance SMD five-year period follow surgical procedure implant cell .</brief_summary>
	<brief_title>A Follow Study Determine Safety Tolerability Sub-retinal Transplantation Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial ( hESC-RPE ) Cells Patients With Stargardt 's Macular Dystrophy ( SMD )</brief_title>
	<detailed_description>This study long-term , extension Phase I/II , open-label , non-randomized , 4-cohort , multi-center clinical trial ( refer core trial core protocol ) maximum 12 SMD patient transplant sequential dos hESC-RPE cell , start dose 50,000 hESC-RPE cell transplant increase maximum dose 200,000 hESC-RPE cell transplant . Eligible patient sign consent form extension study , fulfill inclusion/exclusion criterion . The first visit extension protocol correspond last visit core protocol , take place 12 month post-cell implantation . During first year completion core protocol , i.e . Year 1 Year 2 post-transplantation , patient evaluate approximately 6-month interval ; Year 3 , Year 4 Year 5 post-transplantation , patient evaluate annually . Follow-up include obtain information visual acuity , ophthalmological finding adverse event ( AEs ) , specifically include cancer , neurological , autoimmune hematological disorder develop worsen since last visit .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Must meet eligibility core protocol . Able understand willing sign inform consent participate followup . Treated hESCRPE cell transplant core protocol . Unwilling unable participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Stargardt 's Macular Dystrophy</keyword>
	<keyword>Retinal Diseases</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>fundus flavimaculatus</keyword>
	<keyword>hESC-RPE</keyword>
	<keyword>juvenile macular dystrophy</keyword>
	<keyword>SMD</keyword>
</DOC>